SCHEMBL17512466

SCHEMBL17512466

CCOC(=O)c1ncc(N)cc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.46
LMNA P02545 1/20 0.46
CYP3A4 P08684 1/20 0.46
MAOA P21397 1/20 0.46
ALDH1A1 P00352 5/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 1/20 0.44
KDM4E B2RXH2 3/20 0.43
MAPK1 P28482 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HSP90AA1 P07900 1/20 0.42
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPC1 O15118 4/20 0.41
HSD17B10 Q99714 2/20 0.41
RAB9A P51151 2/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
XBP1 P17861 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24131085 0.87 CYP1A2 (0.46) CYP1A2LMNACYP3A4MAOAALDH1A1
SCHEMBL8318161 0.85 ALDH1A1 (0.50) CYP1A2LMNACYP3A4MAOAALDH1A1
SCHEMBL25765775 0.83 KDM4E (0.46) CYP1A2CYP3A4ALDH1A1KMT2AKDM4E
SCHEMBL5820179 0.83 NPSR1 (0.42) CYP3A4ALDH1A1KDM4EMAPK1L3MBTL1
SCHEMBL5820404 0.83 GABRA1 (0.48) CYP1A2LMNACYP3A4MAOAALDH1A1
SCHEMBL15351111 0.81 CYP2C19 (0.54) CYP1A2LMNACYP3A4MAOAALDH1A1
SCHEMBL17986657 0.80 CYP1A2 (0.41) CYP1A2LMNACYP3A4MAOAALDH1A1
SCHEMBL22061414 0.80 MAPK1 (0.43) CYP1A2CYP3A4ALDH1A1KMT2AKDM4E
SCHEMBL4674787 0.80 OPRK1 (0.44) ALDH1A1KMT2AMEN1KDM4EMAPK1
SCHEMBL10269771 0.79 CYP2C19 (0.59) CYP1A2LMNAALDH1A1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3617195-B1 NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVES AS INHIBITORS OF TROPOMYOSIN RECEPTOR KINASE A FOR THE TREATMENT OF PAIN MOCHIDA PHARM CO LTD (JP) 2024-08-28 EP disclosed
CN-110831926-B Tetrahydronaphtyl urea derivatives 持田制药株式会社 2023-11-21 CN disclosed
US-11197867-B2 Aminopyrimidinyl compounds PFIZER INC. (US) 2021-12-14 US disclosed
US-20210377495-A1 AMINOPYRIMIDINYL COMPOUNDS PFIZER INC. (US) 2021-12-02 US disclosed
US-10980815-B2 Aminopyrimidinyl compounds PFIZER INC. (US) 2021-04-20 US disclosed
US-10927079-B2 Intermediate compound of novel tetrahydronaphthyl urea derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2021-02-23 US disclosed
US-20200330477-A1 AMINOPYRIMIDINYL COMPOUNDS PFIZER INC. (US) 2020-10-22 US disclosed
US-20200239419-A1 NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2020-07-30 US disclosed
US-10669239-B2 Tetrahydronaphthyl urea derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2020-06-02 US disclosed
EP-3617195-A1 NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVES Mochida Pharmaceutical Co., Ltd. (JP) 2020-03-04 EP disclosed
US-10463675-B2 Aminopyrimidinyl compounds PFIZER INC. (US) 2019-11-05 US disclosed
US-10399945-B2 Tetrahydronaphthyl urea derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2019-09-03 US disclosed
US-20190023657-A1 NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2019-01-24 US disclosed
EP-3183247-B9 AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS PFIZER (US) 2018-07-25 EP disclosed
EP-3183247-B1 AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS PFIZER (US) 2017-11-29 EP disclosed
US-20170239264-A1 AMINOPYRIMIDINYL COMPOUNDS PFIZER INC. (US) 2017-08-24 US disclosed
EP-3183247-A1 AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS Pfizer Inc (US) 2017-06-28 EP disclosed
US-9663526-B2 Aminopyrimidinyl compounds PFIZER INC. (US) 2017-05-30 US disclosed
US-20160052930-A1 AMINOPYRIMIDINYL COMPOUNDS PFIZER INC. (US) 2016-02-25 US disclosed
WO-2016027195-A1 AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS PFIZER INC. (US) 2016-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239419-A1 NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE CCNT2, UTS2R, DIMT1 CYP1A2 469/4885LMNA 2674/4885CYP3A4 1081/4885
US-10927079-B2 Intermediate compound of novel tetrahydronaphthyl urea derivative CCNT2, DIMT1, QTRT2 CYP1A2 487/4885LMNA 2279/4885CYP3A4 897/4885
US-10399945-B2 Tetrahydronaphthyl urea derivative OPRL1, TRPV1, TSLP CYP1A2 4015/4885LMNA 3510/4885CYP3A4 2896/4885
US-10463675-B2 Aminopyrimidinyl compounds JAK2, JAK1, JAK3 CYP1A2 3673/4885LMNA 3955/4885CYP3A4 2256/4885
US-11197867-B2 Aminopyrimidinyl compounds CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SSTR3 CYP1A2 2353/4885LMNA 2168/4885CYP3A4 1478/4885
US-10980815-B2 Aminopyrimidinyl compounds JAK2, JAK1, JAK3 CYP1A2 3673/4885LMNA 3955/4885CYP3A4 2256/4885
US-20200330477-A1 AMINOPYRIMIDINYL COMPOUNDS CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SSTR3 CYP1A2 2353/4885LMNA 2168/4885CYP3A4 1478/4885
US-20170239264-A1 AMINOPYRIMIDINYL COMPOUNDS CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3 CYP1A2 2037/4885LMNA 2090/4885CYP3A4 1316/4885
US-20160052930-A1 AMINOPYRIMIDINYL COMPOUNDS CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3 CYP1A2 2037/4885LMNA 2090/4885CYP3A4 1316/4885
US-10669239-B2 Tetrahydronaphthyl urea derivative OPRL1, TRPV1, UTS2R CYP1A2 4245/4885LMNA 3431/4885CYP3A4 2978/4885
US-20190023657-A1 NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE UTS2R, OPRL1, TRPV1 CYP1A2 3934/4885LMNA 3680/4885CYP3A4 2812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.